Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

Afatinib Efficacious in EGFR+ NSCLC Harboring Major Uncommon Mutations, Irrespective of Ethnicity

posted 2 days

Mashup Score: 4

OncLive - Afatinib was found to be effective when used in Asian and non-Asian patients with non–small cell lung cancer with major uncommon and compound EGFR...

NICE Recommends Isatuximab Plus Pomalidomide/Dexamethasone for Relapsed/Refractory Myeloma

posted 1 day

Mashup Score: 3

OncLive - The United Kingdom’s National Institute for Health and Care Excellence has recommended isatuximab-irfc in combination with pomalidomide and dexamethasone as a treatment option for...

  • The United Kingdom’s National Institute for Health and Care Excellence has recommended isatuximab in combination with pomalidomide and dexamethasone as a treatment option for select patients with relapsed/refractory multiple myeloma. #mmsm https://t.co/P60QGKpsgc

Evaluating New Standards in Extensive-Stage Small Cell Lung Cancer

posted 2 days

Mashup Score: 2

OncLive - Igor I. Rybkin, MD, PhD, discusses the data with these frontline and second-line regimens in extensive-stage small cell lung...

FDA Approves FoundationOne CDx for Larotrectinib in NTRK+ Tumors

posted 23 hours

Mashup Score: 2

OncLive - The FDA has approved the FoundationOne CDx comprehensive genomic test as a companion diagnostic for larotrectinib (Vitrakvi) to identify patients with NTRK1/2/3 gene fusions...

Mentoring Oncologists in the Era of Social Distancing

posted 2 days

Mashup Score: 1

OncLive - Mentoring is critically important to the development of young academic hematology/oncology...

Nivolumab Nears EU Approval for Second-Line Esophageal Squamous Cell Carcinoma

posted 17 hours

Mashup Score: 1

OncLive - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for nivolumab in the treatment of adult patients...

  • The EMA's CHMP has adopted a positive opinion for nivolumab in the treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC following previous fluoropyrimidine- and platinum-based chemotherapy. #esophca https://t.co/XJlvLEjAkS

Join Us to Learn About XPOVIO

posted 1 day

Mashup Score: 1

studio.mjhassoc.com - This live broadcast will be presented by OncLive® and hosted by Karyopharm® Therapeutics. Please use the event date dropdown below to select one of...

FDA Grants Priority Review to Adjuvant Osimertinib for Early-Stage EGFR+ Lung Cancer

posted 38 mins

Mashup Score: 1

OncLive - The FDA has granted osimertinib a priority review designation to a supplemental new drug application for the adjuvant treatment of patients with early-stage EGFR-mutated...

  • The priority review designation for osimertinib was based on the pivotal ADAURA trial, which showed that adjuvant osimertinib resulted in a statistically significant and clinically meaningful improvement in DFS in patients with EGFR-mutated NSCLC. #lcsm https://t.co/fajYZvAm4j

interactive-tools.onclive.com - INDICATIONXPOVIO® (selinexor) is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL...

Trilaciclib Reduces Need for G-CSF, RBC Transfusions From Chemo-Induced AEs in ES-SCLC

posted 12 hours

Mashup Score: 1

OncLive - Treatment with the CDK4/6 inhibitor trilaciclib prior to chemotherapy compared with placebo significantly reduced the need for supportive care interventions in the management of...